Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
Public ClinicalTrials.gov record NCT05743270. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label, Multicenter Study Investigating Oncolytic Immunotherapy in Combination With Other Therapy in Patients With Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
Study identification
- NCT ID
- NCT05743270
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Replimune, Inc.
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- RP3 Biological
- CCRT(concurrent chemoradiation therapy) Other
- carboplatin and paclitaxel Other
- nivolumab Biological
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 29, 2024
- Primary completion
- Feb 28, 2026
- Completion
- May 31, 2026
- Last update posted
- Mar 10, 2025
2024 – 2026
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego, UCSD | La Jolla | California | 92037 | — |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| UCLA Medicine Division of Hematology-Oncology | Los Angeles | California | 90095 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Thomas Jefferson University City Center and Abington | Philadelphia | Pennsylvania | 19107 | — |
| University of Pittsburgh Medical Center, UPMC | Pittsburgh | Pennsylvania | 15232 | — |
| Jefferson Health Abington Asplunhd Cancer Pavillion | Willow Grove | Pennsylvania | 19090 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| University of Washington / Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05743270, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 10, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05743270 live on ClinicalTrials.gov.